Loading...
Market
Will AlphaProteo be licensed for commercial use by a pharmaceutical company by the end of 2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from Google DeepMind or pharmaceutical companies
Story
Google DeepMind Unveils AlphaProteo for High-Strength Protein Binders with 3-300x Better Affinities
Sep 5, 2024, 03:24 PM
Google DeepMind has unveiled AlphaProteo, a new AI system designed to create novel, high-strength protein binders that target specific molecules. AlphaProteo achieves 3-300x better binding affinities and success rates on 7 targets compared to existing methods, making it a significant advancement in drug development, disease diagnosis, and biosensor technology. This system could accelerate the understanding of biological processes and aid in the development of new therapies. AlphaProteo's capabilities, trained on synthetic data from AlphaFold, are expected to outperform existing methods in binding proteins, potentially revolutionizing the field of biotechnology.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
Drug Development • 25%
Agricultural Biotechnology • 25%
Industrial Enzymes • 25%
Other • 25%
0-1 • 25%
2-3 • 25%
4-5 • 25%
More than 5 • 25%
Cancer • 25%
Autoimmune disorders • 25%
Infectious diseases • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Highly Positive • 25%
Moderately Positive • 25%
Neutral • 25%
Negative • 25%